Ballew Advisors’s Edwards Lifesciences EW Stock Holding History

Ballew Advisors’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-9,052	Closed	-$984K	–	125
2021 Q3	$984K	Buy	+9,052	New	+$1.03M	0.72%	39

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ballew Advisors's EW Position: Q4 2021 in Review

Ballew Advisors sold out of Edwards Lifesciences (EW) in Q4 2021, closing a stake of 9,052 shares — an estimated $984K sold.

Ballew Advisors first reported a position in EW in Q3 2021 and held it in 1 quarter. The position peaked at $984K in Q3 2021. 1,320 funds tracked by Wall St. Rank hold EW as of Q4 2021.

Ballew Advisors reported no remaining Edwards Lifesciences position as of Q4 2021 after selling out during the quarter.
Ballew Advisors sold 9,052 Edwards Lifesciences shares in Q4 2021, an estimated $984K.
Ballew Advisors first reported a position in Edwards Lifesciences in Q3 2021 and held it in 1 quarter.
Ballew Advisors's Edwards Lifesciences position peaked at $984K in Q3 2021.
1,320 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2021.

Based on Ballew Advisors's 13F filing for Q4 2021, filed 26 Jan 2022.